CLSD - Earnings call transcript Q4 2018 | Clearside Biomedical, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, ladies and gentlemen and welcome to the Q4 2018 Clearside Biomedical Inc. Earnings Conference Call. At this time, all participants are in a listen-only mode. Later we will conduct a question and answer session and instructions for you to participate will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded. to host like Ms. today's now would introduce for your conference I Kobin Relations. Clearside Jenny Investor of may you Ma'am, begin.

Jenny Kobin

everyone joining call us afternoon, on Good and the today. thank you for

factors remind call XXXX. on website. and Before that these remarks company's that the SEC including this of certain Report like Form report future SEC I during from section quarterly XX-K filed statements Private we Various result Factors on important to and make about March for begin, forward-looking filed Securities statements XXXX the with statements. during XX, will Act we Clearside's ended call quarter of today's we in be those the XXXX Form and all the those for expectations filings XXXX. a the XX, the available making and Litigation Risk would you on ended November XX, the XXXX Annual materially our most September differ by of prospects our Actual for constitute SEC of X, may purposes other recent forward-looking forward-looking on as with indicated year results discussed Reform various December plans XX-Q on

views any our relied and upon day. addition, views subsequent as as as statements In represent should forward-looking our representing today of not be of any

our plans our formal XIPERE; will recently platform applicability the will and if Charlie the review do highlight White, even statements update; Chief the presented forward-looking Daniel Thomas point While our and will our Officer, so, disclaim for Officer, Medical views today's Officer, these Chief obligation data; conclude elect at with summary. provide some Raymond, Executive Brion Commercial future our we financial to update and Chief strategic President to remarks may we CFO, Deignan, specifically change. Dr. our any will call Ciulla, our On of

Daniel. over turn like We open questions. I now would call your then the will for to to the call

Daniel White

Good the Jenny. everyone for us you on you, Thank joining today. afternoon, call thank and

innovative Clearside Our the to is focus deliver pharmacotherapy at to eye. our the of blinding to diseases technology platform using treat back

month We accepted associated are by significant Application, The approach many with therapeutic for proprietary by Clearside provide now for of these treatment. and therapy macular in for will a for in people targeted suspension is XIPERE an drugs that under as suprachoroidal the unique announce with technology then edema uveitis. associated cause Together, marks ophthalmic approved. with for of combines developing New the pleased to loss treatment triamcinolone NDA current macular Drug injection blindness requires diseases. eye acceptance be different leading to therapeutic method intravitreal suprachoroidal This eye unmet a or drug achieve XIPERE edema of indicated uveitis uveitis, that that agents. is is treatment will need the milestone even serious patients. first novel formulation. our XIPERE the and target NDA, vision review our facilitates first the last with more method is acetonide FDA. agency it delivery delivery pharmacotherapy delivering the from platform injection components This was Clearside and injections, part the standard of for administration of for of

patented the first working first We in a acuity locations using our as to anatomic current launch to that just trial. has endpoint have visual first application of October for importantly, diligently their date XIPERE SCS. as is refer the uveitis XX, candidate for the we is uveitic on an or NDA clinical provided into reviewing as a completing the the to process all our study to formally is administration approved, team of and XXXX product space, will is time the If the launch four preparations. goal may corrected this of filing PDUFA conducted And with plan this patients primary best allowed for quarter response FDA The FDA our and first the use regulatory our the suprachoroidal a XXXX. and

In call edema, over further to the our molecules and and platform indications. addition such blinding Tom and I to Ciulla believe this now turn applicability exploring or forward are small for we SCS the first diabetic gene are wet moving platform administration And highlight applicability across our to presented indication we AMD prevalent DME. in broad XIPERE, macular other of diseases We delivery. will has Dr. as recently data. the

Thomas Ciulla

was with visual as eight is legal treatment, following Daniel's U.S. which Thank edema believe To XIPERE results I validates that of the our patients in technique approximately and to of angle half in improvement physician beneficial treatment. you important read patients. the XX% indicating for patients the would with I treatment compared the potential discuss will patients retina and this will Suprachoroidal-administered also reiterate their patients clinical half resulting able represents first expand points potentially early vision The better a ocular in or week therapy armamentarium. suprachoroidal letters some to by the most therapeutic uveitis. driving of visual for edema PEACHTREE, XIPERE over therapies. entry. of Phase vision states. three a Daniel. which all one-half like of XIPERE-treated their size targeted vision, doubling represents Improvement accompanied in development to other as reduction a very following and trial in future macular trial in or I XX/XX why evaluate disease the our achieved choroid novel gained as find platform with and complement much, study to rapidly study vision drug any treatment the suprachoroidal of X a Nearly acuity of the PEACHTREE plan more in XX% XIPERE in at of resolution vision were secondary discussion the XIPERE In was clinically of at to significant of of meaningful exceeded about trial injection lines proportion to platform. macular high-levels

four and Importantly, XIPERE pan-uveitis. posterior demonstrated results in all including anatomic locations anterior, these intermediate,

In the reported were the maintained January, commonly were responses additional nine the for The uveitic patients patients short Corticosteroids weeks PeriOcular and both Recently for dexamethasone additional intravitreal show extension a six-month without after approximately an that clinical who macular in are we local of INTravitreal and their for intravitreal followed to XX or periocular outperformed compared Edema through arm treatment. Macular weeks. letters of durable. the injection XX administered results In compared the NIH-funded in treatment of corticosteroids edema. achieving suprachoroidal that three MAGNOLIA XX PEACHTREE trial second requiring the arm. XX letters XX% study addition, effect in XIPERE-treated total In MAGNOLIA, the Trial four called Uveitic corticosteroid, gained POINT approximately prospective triamcinolone periocular for XIPERE

acuity this the six While gain trial letters directly visual PEACHTREE in XX.X was we months. at cannot with mean compare

standard clinical the for two-thirds in With fact potential of medications. of is that required our resolved label POINT considering the patients patients intraocular one-fourth IOP. team the or in of IOP-lowering Additionally to alongside XIPERE. only of arm study for PEACHTREE, addition of in In pressure size PEACHTREE, this approximately data, required information medications the patients plans X.X% over to in the expansion lower one-third each

but medical monotherapy, In Eylea to with provide over patients. in to six-month scientific XIPERE XIPERE benefit acuity. statistically to similar or from believe and the monotherapy was improvement landscape, edema and expand visual we X advisers of results where evaluation mean in EYLEA the TYBEE also time are based the our treatment a DME We period. macular in XIPERE combination on looking label This fewer our significant with diabetic Phase with treatments can consultation DME study administered achieved

a clinical U.S. into discuss anti-VEGF preparing result, we As therapeutic the rotation DME. development monotherapy with XIPERE with advance forward materials FDA the path currently of the for to are a to

Let about excited particularly area me I'm tell for you another Clearside. about that

for are gene-based work those activity therapies. retina non-viral DNA tolerated the of in the underwent suprachoroidal was eyes administration. Interestingly, in Szilard Suprachoroidal gene therapy injected of suprachoroidally. was non-viral abnormalities. no suprachoroidal marker data with eyes marker choroid preliminary therapy. administration small groups that also In gene well preclinical evidence first preclinical therapy nanoparticle providing in presentation suprachoroidal suprachoroidal he delivery DNA described molecules Dr. comparable provides Macular and This presented February, a of to investigating evidence therapies. those activity our potential potential with non-clinical injection other This Beyond produced administration with based Kiss' gene gene gene was of traditional Society, administration a the of model XIPERE, at all nanoparticle Dr. for significant across eyes. which preliminary subretinal Kiss of platform and gene In we generally more underwent

the platform about subretinal this We the of safer ocular offers potential therapy our particularly for are without surgery targeted administration. risk excited and as possibility gene

the Specifically of consequently enhance therapy retina. access compromised could since suprachoroidal the the injection of epithelium training of detachment therapy the gene not is does minimal of and an centers. both it we further now access. expanding gene ocular value treatment therapy. by improving exploring therapy gene nonviral does not Suprachoroidal viral potentially photoreceptors avoids already require pigment injection retinal Consequently patient and and proposition Suprachoroidal subretinal from and require administration are safety may to administration risk specialized procedure enhance gene ultimately

and agent for first about We which potential milestone our significant suprachoroidal is of first indication, delivery our a are the drug a platform. excited approval

DME. to For uveitis, indications XIPERE and we within our inflammation expand hope

suprachoroidal I We our the to will Chief for and broad areas to explore Brion believe Officer our utilizing Raymond, our over gene Commercial other with an now also and XIPERE. on other in update provide has molecules continue small applicability turn therapy. our plans call platform to administration

Brion Raymond

disease of patients With by for and leading cause has associated we our with of step with to macular edema. world a Uveitis that one Tom. XIPERE approved approximately in will diagnosed be patients are FDA Thank currently affects impairment vision XXX,XXX the with patients uveitis, and developed you, in one-third number the accepted that blindness launching for a U.S. the therapies. approximately closer annually. Of macular no those NDA review, is edema

numerous this the given from population. PEACHTREE an demonstrated edema injection believe function, positive or the triamcinolone is local macular often mentioned, the periocularly which uveitis vision adds our corticosteroids trial visual suprachoroidal that bringing potential our Daniel patients. disease. loss a this to for The to Phase patient cause approach known It people more injection. over in underserved provide benefits of as may primary of intravitreally years of of treating benefit subtenon via results loss topically, We administrating younger to potential X treatment in importance resulting the As also affects

after patient’s maintained released came validation program this extension of when Tom year their MAGNOLIA treatments office through expressed second the XX% -- earlier visits. their for suprachoroidal treated requiring doctor's they months effects patients injection. the burden As durability importance to study, the our further as of for that discussed on we reduce have look nine fewer produce XIPERE Clinicians showing to by data and

will we variety of can For in physicians we uveitis small injection ocular our and approaches physicians and eye retina obtain be a set to routinely this broad the the believe force. launch, steroids use are with concentrated diseases. familiar approximately of specialists We These focused with targeting a U.S. sales treat X,XXX traction with

will comfortable So of use be they platform. with we expect the our

need uveitis. associated Importantly edema with their for macular it an with unmet fills patients

be and on an bill and and reimbursement For therapy our physicians; to and purchase support our physician injection our field-based therapeutic, complement means efforts force team we hub. specific focused practices the launch, training key drug billing Therefore, and with and sales small with will educate for for we interactions will and a physician support patient patient their areas; patients. buy treat bill to which then insurers education; practices the be support. their with reimbursement the office and will intend to administered use three a XIPERE are coding

XIPERE Additionally a payers small to and for payer their value working be relations the provides will educate team customers. on it

begun on launch now our We execute plan. to have

XXXX if our formally XIPERE XX the of first we date; quarter October timing approved. the of in to expect PDUFA Given launch

our our X additional launch approval. extension feedback confident and study Phase we'll the receive the and opinion we able key successfully data positive study, should be we're XIPERE With FDA from to from leaders, efficacy encouraging data from differentiate the

to Charlie Now fourth to review to our the Financial over Chief I'd our Officer, results. financial XXXX Deignan turn like quarter call

Charlie Deignan

in of and was fourth In $X.XX increase and clinical development XXXX The increase related year. compared General the $XX.X research attributable quarter quarter. XXXX, marketing-related compared Thanks, XXXX expenses primarily commercialization administrative retinal fourth in fourth were expenses potential to the costs to one-time to compared was $X.X in the share the including development to the to programs Clearside's for Phase of the were per related share, employee-related expense. $X.X prepare of down was The closing $X.X research two the $X.X quarter $XX.X million $XX.X The was Brion. $XX.X increase vein $X.XX related for million X expenses studies million million, year-ago for quarter. the higher last of in Clearside's year-ago occlusion million to clinical the as net net and The per or loss million development year-ago loss costs quarter mostly or we million primarily and quarter. to million XIPERE.

stock of proceeds common have our short-term $XX.X augmented XX, cash year-end equivalents December investments under with then $X.X net we balance million XXXX our our cash, cash sales facility. and from Since of As of XXXX totaled aftermarket million. approximately

we we R&D launch shutting current operations funds near-term the the priorities over our look associated closing planned XXXX. expenses by commercializing plans our available into trials with that, of our and have our the development sufficient XIPERE for resources for the back and our potential This we launch to to XIPERE. Based research of anticipated allocating turn down treatment Daniel I'll funding of including the the and fund forward, quarter edema activities his reduced facilities are And includes for expect XIPERE, clinical to As to macular uveitis. remarks. on RVO Daniel? of ongoing with call have first

Daniel White

diseases discovered. injection. Clearside, on of We candidates believe platform promise deliver a the care as This potential to and Charlie. rights We this scientists hold standard therapeutic that product U.S. therapeutic innovative develop pharmacologic an treatment of we for our for choroidal agents is diseases. the approach around of intend retinal world. eye founding the exciting the via patients time the commercialize leverage for We to we to the become you and the developed and of exclusive our suprachoroidal Thank the platform difference through for to has in make the treatment

with provide. our is for to and in our and have call plan global expertise operator support the to successful our and We broader indications, pipeline appreciate action provide prudently work Our potential ophthalmic regulatory complete prepare reach. launch, uveitis partners build commitment advancing ask leverage Clearside process, our platform and a a for expand the up including investigators, Operator? employees I'd stakeholders, to patients, to the valuable many the to questions. of the who shareholders, treatment analysts understanding can open now to like

Operator

Thank Anupam you. [Operator first comes from Instructions] Our Rama with JPMorgan. question

is Your line open. now

Tessa Romero

Thank experiences publishing were Tessa is are and also post-hoc comment and update that on going provide our And sounds on here for the on may be you with This FDA As how ongoing? for you updates next Anupam are DME? questions. towards recall an have analysis Can other might I to think what maybe shed here? RVO acknowledging both you taking on the guys might working XIPERE? when peer-reviewed monotherapy today. any you articles clinical to you the for And in potential pursue color do it if valuable on relatedly can discussions do that light I we could, like then indications that

Daniel White

that Tessa, vein question. to and also occlusion. the you about Thanks knew I'll well. other that appreciate questions Ciulla as answer retinal Tom cover be ask your a there'd first one We question have

Thomas Ciulla

Yes.

found combination XX% of for as achieving for know the at endpoint. So primary we well lines with -- that you patients SAPPHIRE, three of around vision performs therapy

studies. additional the therapy regimen we of is the However, the benefit the XIPERE. confirmed so well asked any unable combination benefit monthly we're out anti-VEGF analysis therefore essentially performed of Further to not initial discontinued very expansion because additional any arm Eylea provide discontinued and trial the the that that therapy tease And you has did combination for because analysis of monotherapy about our performed strict well. then monotherapy

do meet the some meeting meetings meeting. FDA We to schedule the Phase prepare timing questions are but to of half discuss DME products as other of the indications. them a isn't a prepare for for and of the in year. outside -- second uveitis, indications so that the II set, approval and with materials hope with there's as The we TYBEE XIPERE currently other considering in trial monotherapy much want and to we of steroid use role potential We we as of these feel we our

Daniel White

And one additional know that. was Tessa I there if question. don't we answered

Tessa Romero

progress. much It’s congrats and was on guys. That the perfect. -- very you you. helpful Thank Thank no super

Daniel White

you, Thank Tessa.

Operator

our Thank question you. Annabel Stifel. next comes Samimy from And with

line Your is open. now

Nick Rubino

wondering the do on taking necessary XIPERE? the the you? landscape on just implants thoughts This for an are physicians you small training afternoon start for specifics Thanks efforts launch? to Rubino market Annabel. I leave everyone. competitive treatment Have Good you And Nick could to we're launch in what have questions. fragmented preparation whether is uveitis' of able of our been Thanks. guess, on and new for the of steroid then any already educate more

Daniel White

the Thank your question. Nick. I Brion that's up appreciate you, alley.

Brion Raymond

training First the on needs. injection

rapidly in implants reps; training train the chronic includes well according those them three-year really technique first training new and Whereas And injection nothing suprachoroidal and us learning believe things the the design -- physicians the they'll sales for and if to the all XIPERE in is cure that's is as they in injection prep to first us role helping then edema, the past really and over ensure but when Retisert actually peer-to-peer after. they as there's year, on a And the an be that see be from as if injection competitive being require patient great multi-faceted that will This to we'll therapy. small, So that, by run. we're need to that And and walks have all those program XIPERE the to long going it their intravitreal if developing is is I base our been treat to the training needs persist the play prior Yutiq of what advanced companies a they've physician to our advisers uveitis. patients patients we includes are online as we can standpoint, a kind well that a new to like taught injection. technique provide. positioned but can similar that

Nick Rubino

Thank sounds All you much. right, good. great, very

Operator

Thank you.

Our Moussatos Securities. Wedbush comes with Liana next question from

open. Your line is now

Liana Moussatos

you my for questions. taking Thank

can this the reps addition how other education, hire? Also on are you update medical start In And to us many you when to launch sales will hiring them? preparations you year? going

Brion Raymond

Sure.

So priorities are injection the top both on as education once procedure I mentioned, data receive and and the we physician our patient approval.

market Second is this at. be force perspective, this incorporation force of extent in way a of reach with that drug this of top a all to Definitely sales we're reimbursement But large under the the that point alignments With territory able and product, reach sales we customers. a first is reimbursement force. can looking XX through and and have be we've along sales three what at or deciding practice order successful we're concentrated initiating our how able are exactly our all a really really the into to to how support. reps a the said small is still we'd third a working assisting training we're buy-and-bill priorities. injection all From of and this the to through being staffing

payer there very field a have also we'll a I Liana Was team to? them, get and didn't reimbursement practices. to question that payers and supporting addition both another team small In

Liana Moussatos

hiring start you will reps? sales When

Brion Raymond

offers ourselves make upon approval. to contingent decided We've

contingent So sales the leadership reps will field their upon soon, team and bringing the other offers onboard approval. begin a but actual be we'll reps

Liana Moussatos

Thank you.

Operator

you. Thank

from Our with Needham. next Belanger comes question Serge

open. now is line Your

Tian Sun

Thank for Tian you MAGNOLIA your have who you Serge. did But different other XX the something my extension it you. Hey, not on need that have color maybe XX% medications? any that population? Was this to guess of I Is medications. plan of Most patients been is questions additional to the data about on there patients And need through XX% material? into do did any this where receive half supplement weeks for the answered. of additional marketing something showed

Daniel White

answer you Why that any or the Tom, about reverse? color do we didn't in don't retreatment. Let's question talk have require not who receive to patients, that? did

Thomas Ciulla

Sure.

may observation So know as prospective MAGNOLIA PEACHTREE. masked XX a non-interventional of week was you extension

for we rescued, in basically we what who MAGNOLIA rescued patients that need order patients second from And were extension PEACHTREE approximately not did patients get regard PEACHTREE and study. basically rescue were of end was found of study their PEACHTREE So durability. not And exited XX in the information half as the more which the did were to at after the the weeks they this eligible in XX protocol-mandated week beginning dose. to the with

So if question. I answers don't that know your

Daniel White

other the And Yes. half?

Thomas Ciulla

exited rescued were So half the other they as they MAGNOLIA.

Tian Sun

That makes sense you. Got more Thanks. now.

Daniel White

definition by the that color three to PEACHTREE so to had months just at have to of gone end least at to would And to it. they add be for qualify

Tian Sun

you. Got

Brion Raymond

don't MAGNOLIA answer. we FDA. from marketing unfortunately, And with But discussing I a the data a will using perspective, have be the great

and will on are However, deliberations ongoing currently our until date. PDUFA continue to those go

really can't not perspective. use be we'll whether or I to a So able from that marketing answer

Tian Sun

Got you. very Those Thanks. helpful.

Daniel White

You’re welcome.

Operator

you. Thank

Brisebois Our comes from next with question Laidlaw. François

line now Your open. is

François Brisebois

for competition that? answer will just do kind in attack on kind of the short of how maybe you when that interesting Thanks generic for think you terms steroids, community the acting was guys. was the the Most competition have I'm wondering, been questions. – cheaper three-year implants. talked taking but of Hey, about answered, medical the I wondering

Daniel White

to question. the a little great presentation around that a that's Frank, our Study. bit We remarks try illustrate in POINT

who come the patients? typically drop – that treatments, or they'll not a then Of disease since generic not to many or and did go then receive you've that of talk adequately know, uveitis to macular about seen if Tom, don't they're some that state And they're infectious. edema into where these critical – be tested why going associated patients automatically in, whether illustrative those see you infectious theme with result treated. are patients can they not a in you These is blindness, as So regimen.

Thomas Ciulla

Sure.

a question. it's So, great

commonly is to local triamcinolone. edema. Daniel the were PEACHTREE, one this POINT those Study, three there to to compared which to although and with nine compare And treatment about macular the with in interocular of letters a to letters. of patients alluded what's had As for about was point important patients six note we were And directly periocular. interesting the uveitic One Two corticosteroids was used generic out can't corticosteroids XX.X in we it months. periocular improved interocular the is gain injection that four letter at by PEACHTREE,

Additionally, or PEACHTREE even we the approximately to to that more in of patients directly these but of medication required to medications. IOP only their importantly, required and is Study compare in the X.X% one-third arms lowering lower addition of intriguing POINT IOP, in can't note patients one-quarter the again, it it,

So – I think

Brion Raymond

Whereas Yeah. I two YUTIQ safety would of and the anterior all or segment. our perspective, competitive a anatomic and uveitis there our patients the Tom that posterior quoted locations when was indicated mentioned after of one OZURDEX that this and And and macular competitive you Liana's with like triamcinolone edema. I injection uveitis including after products. of to is see posterior trial are rates everyone question sort also that I and data just our injections out involving included standpoint, From paid remind are from approved uveitis for, a answering only for

So, competitively in get the I stack nicely market. up when think we we

Daniel White

was where clinical that for in the their many corticosteroids programs. trial And to allowed end I the exclusion think criteria an additionally long-acting of we of patients come

between are that to making like impact a we we products. risk-benefit meaningful of these on any believe So, profile the

François Brisebois

great. That's

answer. that's in-depth Now, helpful very

I So data of the transition indication -- of that kind preclinical and could then how between in kind data talk therapy or really switch about from gene the usually? to this clinical angle that interesting. think therapy, to to gene Can is in relationship you relate

Daniel White

Yes.

to the to the further target. this with for Clearside Daniel. -- looking And closely is key are at working teams in area discovery the So, XIPERE launch our who has development. particularly its not team very of commend this or been I identify want associated

closed approaches viral we this AAV and last data viral that capsid as both other that species means even that of demonstrate As and a both injection. from sub-retinal were as found without expression year year equivalent out we approaches primate non-viral in some we non-human to well animal and able to in

marker course. using that's of genes, Now,

therapeutic we So, we've several our fascinating. but this joined we targets that talent them on to have to the add marker a company of and through team that about terrific take you color We're for we've and later gene like going taken that? believe information very recently this Tom unique would are talk date, capabilities now we who's some to approach. delivering more identified

Thomas Ciulla

Sure.

approved gene for So, as of the cones both And as in gene therapy to sub-retinal plan essentially rods the temporarily investigational detached the exposed to part significant require gene you of know sub-retinal the retinotomy the a can and so or retinal epithelium. pigment surgery. a attracting therapy only this That disease created as retinal well this a the many be retina that therapies hole of in in is surgery is perform risk. entails small that and is the retina obviously photoreceptor

you're already retina. detachment addition a retinal creating in compromised an In

or also cannot we become -- therapy administer we the risk minimally example office-based if our with circumvent can an for have risk so procedure. enhance suprachoroidal this sub-retinal of approach surgery potentially of gene And patient invasively injection that access and

a So, injection if almost would surgery. to from yield those that may actually suprachoroidal translation a trials to preclinical see we simpler therapies are think benefit therapies gene to perform there's the and have clinical, of translation some wish you risk investigational already of without asked where the I about can

it's has I safety advantages advantages. of So, administration, and think it's a effective, if very because translation clearly patient the route simple access

Daniel White

doing universities a taking develop and well down worth companies to we're that within this. major we been as We trying launch therapy with path. where collaborating that our from concept it's R&D. to provide we and as immediate We've a gene approach build mentioning terrific go stand own the expertise also continue well a I help think very company well product as point -- this to prudent at company, as many develop their as this as to and opportunity from view perhaps as understand of

Thomas Ciulla

like to I'd paradigm With a is gene more in just there point. potential add to therapy. change one the suprachoroidal entire injection,

therapy difficult to immune gene repeat is response. have capsid now, right Specifically, creates which maybe an a because you virus

is to for In surgery difficult also addition, performing reasons. repeat sub-retinal safety really

the suprachoroidal repeated. we're administer interested doesn't can potential the with non-viral injection, and and that to we So, that approach be gene inflammation in have because induce repeat therapy

invasive. we with So, that to a injected approach repeatable a the there's for nonviral a -- gene repeatedly therapy be it's suprachoroidal because minimally potential is approach

technologies these And to marry two so, synergies. achieve some can we significant

Francois Brisebois

Okay. Thank you. me. very for Great. That’s helpful. That’s it

Daniel White

Thank you, Frank.

Operator

Thank a Liana with you. we follow-up from And Moussatos Securities. Wedbush have

is now open. Your line

Liana Moussatos

You've a or therapy been next gene gene lot injection? therapy. molecule about small for program be Clearside the Will SCS for talking

Daniel White

That's Liana, question. thank great you. a

we some forward I to our going, the is again, into where future company my look targets. for want very very team developing commend As about granular, approachable

gene which are of Some therapy.

those are which And of continue in areas. small molecules. our to collaborations of Some both advance

of there's -- we us targets the chance what think best appropriate do that to us is give the I success. have pick candidate for to prioritize these

for And -- small reminder treat a is other to that can molecule not some be these launched, area XIPERE diseases. space being it the are just our retinal what consider could showing well indications we XIPERE was applied is While that go molecule that model and outstanding as triamcinolone a is and for. is only to as as an of suprachoroidal the

Liana Moussatos

more that in anticipate or a is XXXX? you program Do XXXX, new

Daniel White

I have an answer can't really that. for

I you have with like means to what to and into in get you a we so future would that Thank define date. much. First, program

Liana Moussatos

Thank you.

Operator

call like in Thank I'm over closing White, further I'd you. Daniel showing And queue at remarks. any this CEO, and to the the to for President no questions back turn time.

Daniel White

again once appreciate forward Clearside you now the disconnect. for your continued interest look Operator, to on updating and us progress. Thank today. in We call we joining on you you our may

Operator

Thank you. thank Ladies your and participation. for gentlemen, you

may You Everyone great all have disconnect. day. a

Clearside Biomedical (CLSD) 12 Mar 192018 Q4 Earnings call transcript